GlucoTrack establishes Patient Advisory Board

Glucotrack (GCTK) announced the formation of a Patient Advisory Board comprised of leading patient voices and advocates within the diabetes community. Following the successful completion of the Company’s first-in-human clinical study, the PAB includes individuals with firsthand experiences and understanding of the impact diabetes management has on daily living. Establishing the PAB aims to keep patients’ insights at the forefront of Glucotrack’s development plans for its long-term implantable Continuous Blood Glucose Monitor. The inaugural PAB meeting was held on May 3, 2025. The insights and feedback from this board will make a significant impact on every stage of the CBGM, from clinical to commercial. The board will convene regularly to provide insights on living with diabetes, current management challenges and feedback on Glucotrack’s product development and commercialization strategies.